Davita Inc (NYSE:DVA) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totalling 9,590,100 shares, an increase of 17.4% from the June 15th total of 8,166,200 shares. Based on an average daily trading volume, of 1,920,000 shares, the short-interest ratio is currently 5.0 days. Currently, 5.9% of the shares of the stock are sold short.

Several equities analysts have recently weighed in on the stock. TheStreet downgraded shares of VF from a “b+” rating to a “c” rating in a research note on Wednesday. Zacks Investment Research upgraded shares of Garrett Motion from a “sell” rating to a “hold” rating in a research report on Friday, May 10th. ValuEngine upgraded shares of Zumiez from a “sell” rating to a “hold” rating in a research report on Monday, July 22nd. William Blair restated an “outperform” rating on shares of American Software in a research report on Thursday, June 20th. Finally, Deutsche Bank cut shares of Mitsubishi Motors from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th. Eight investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $67.06.

Institutional investors and hedge funds have recently made changes to their positions in the business. Rehmann Capital Advisory Group increased its position in shares of Davita by 467.3% during the first quarter. Rehmann Capital Advisory Group now owns 556 shares of the company’s stock valued at $30,000 after acquiring an additional 458 shares during the last quarter. Clearbridge Investments LLC increased its position in shares of Davita by 63.5% during the first quarter. Clearbridge Investments LLC now owns 798 shares of the company’s stock valued at $43,000 after acquiring an additional 310 shares during the last quarter. CSat Investment Advisory L.P. increased its position in shares of Davita by 54.0% during the first quarter. CSat Investment Advisory L.P. now owns 895 shares of the company’s stock valued at $49,000 after acquiring an additional 314 shares during the last quarter. Quadrant Capital Group LLC increased its position in shares of Davita by 2,481.1% during the first quarter. Quadrant Capital Group LLC now owns 955 shares of the company’s stock valued at $50,000 after acquiring an additional 918 shares during the last quarter. Finally, First Interstate Bank acquired a new stake in shares of Davita during the first quarter valued at about $65,000. Institutional investors and hedge funds own 87.68% of the company’s stock.

Davita stock traded up $0.47 during midday trading on Friday, hitting $59.40. 2,103,079 shares of the stock were exchanged, compared to its average volume of 2,432,711. Davita has a fifty-two week low of $43.40 and a fifty-two week high of $79.11. The firm has a market cap of $9.88 billion, a PE ratio of 16.64, a price-to-earnings-growth ratio of 0.63 and a beta of 1.59. The stock’s 50-day moving average price is $54.34. The company has a debt-to-equity ratio of 2.06, a current ratio of 1.12 and a quick ratio of 1.11.

Davita (NYSE:DVA) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.91 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.95 by ($0.04). Davita had a return on equity of 13.96% and a net margin of 1.15%. The firm had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.82 billion. During the same quarter in the previous year, the business posted $1.05 earnings per share. Davita’s revenue for the quarter was down 3.7% on a year-over-year basis. As a group, equities analysts anticipate that Davita will post 4.31 EPS for the current fiscal year.

About Davita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Story: Should You Consider an Index Fund?

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.